30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q14 Revenue: Anika Therapeutics

  • Orthobiologics sales $18.9MM, +47%
  • ORTHOVISC sales from Mitek +15%
  • Ex-U.S. MONOVISC +40%


  • Notes weak European economies and slower than planned expansion in EMEA markets impacting ORTHOVISC sales
  • Majority of U.S. MONOVISC sales reflect conversions from competing single-injection products (vs. ORTHOVISC cannibalization, which is occurring in a number of ex-U.S. markets)
  • Signed MONOVISC distribution agreements in Taiwan, Hong Kong and Japan
  • Seeks to reach 15% share of global viscosupplementation market by end of 2018
  • In 4Q, announced unique CMS J-Code for MONOVISC, effective 1/15
  • On track to begin Hyalofast cartilage repair U.S. Investigational Device human clinical trial in mid-2015
  • Completed patient follow-up for Cingal Phase III clinical trial; initiated planning on open label extension study to support a re-treatment indication